{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T14:58:41Z","timestamp":1775487521562,"version":"3.50.1"},"reference-count":72,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,3,1]],"date-time":"2018-03-01T00:00:00Z","timestamp":1519862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","ejpn-journal.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Paediatric Neurology"],"published-print":{"date-parts":[[2018,3]]},"DOI":"10.1016\/j.ejpn.2017.11.010","type":"journal-article","created":{"date-parts":[[2017,12,19]],"date-time":"2017-12-19T18:43:03Z","timestamp":1513708983000},"page":"292-300","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Principles and approaches to the treatment of immune-mediated movement disorders"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1219-4781","authenticated-orcid":false,"given":"Shekeeb S.","family":"Mohammad","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Russell C.","family":"Dale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpn.2017.11.010_bib1","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/j.1469-8749.2009.03598.x","article-title":"A prospective study of acute movement disorders in children","volume":"52","author":"Dale","year":"2010","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.ejpn.2017.11.010_bib2","doi-asserted-by":"crossref","first-page":"e974","DOI":"10.1542\/peds.2014-2702","article-title":"Infectious and autoantibody-associated encephalitis: clinical features and long-term outcome","volume":"135","author":"Pillai","year":"2015","journal-title":"Pediatrics"},{"key":"10.1016\/j.ejpn.2017.11.010_bib3","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S1474-4422(10)70253-2","article-title":"Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis","volume":"10","author":"Dalmau","year":"2011","journal-title":"Lancet Neurol"},{"issue":"7","key":"10.1016\/j.ejpn.2017.11.010_bib4","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1111\/dmcn.13420","article-title":"Anti-N-methyl-d-aspartate receptor encephalitis in M\u0101ori and Pacific Island children in New Zealand","volume":"59","author":"Jones","year":"2017","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.ejpn.2017.11.010_bib5","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S1474-4422(12)70310-1","article-title":"Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study","volume":"12","author":"Titulaer","year":"2013","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.ejpn.2017.11.010_bib6","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/B978-0-444-52014-2.00014-8","article-title":"Sydenham's chorea","volume":"100","author":"Cardoso","year":"2011","journal-title":"Handb Clin Neurol"},{"key":"10.1016\/j.ejpn.2017.11.010_bib7","doi-asserted-by":"crossref","first-page":"e388","DOI":"10.1542\/peds.2010-3114","article-title":"Outcome and prognostic features in opsoclonus-myoclonus syndrome from infancy to adult life","volume":"128","author":"Brunklaus","year":"2011","journal-title":"Pediatrics"},{"key":"10.1016\/j.ejpn.2017.11.010_bib8","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/mds.25999","article-title":"Movement disorders in children with anti-NMDAR encephalitis and other autoimmune encephalopathies","volume":"29","author":"Mohammad","year":"2014","journal-title":"Mov Disord"},{"key":"10.1016\/j.ejpn.2017.11.010_bib9","article-title":"From research subgroup to clinical syndrome: modifying the PANDAS criteria to describe PANS (Pediatric Acute-onset Neuropsychiatric Syndrome)","volume":"2012","author":"Swedo","year":"2012","journal-title":"Pediatr Therapeut"},{"key":"10.1016\/j.ejpn.2017.11.010_bib10","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1089\/cap.2014.0084","article-title":"Clinical evaluation of youth with pediatric acute-onset neuropsychiatric syndrome (PANS): recommendations from the 2013 PANS Consensus Conference","volume":"25","author":"Chang","year":"2015","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.ejpn.2017.11.010_bib11","doi-asserted-by":"crossref","first-page":"5866","DOI":"10.1523\/JNEUROSCI.0167-10.2010","article-title":"Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis","volume":"30","author":"Hughes","year":"2010","journal-title":"J Neurosci"},{"key":"10.1016\/j.ejpn.2017.11.010_bib12","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1093\/brain\/awu310","article-title":"Human N-methyl D-aspartate receptor antibodies alter memory and behaviour in mice","volume":"138","author":"Planaguma","year":"2015","journal-title":"Brain"},{"key":"10.1016\/j.ejpn.2017.11.010_bib13","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1001\/jamaneurol.2014.2956","article-title":"Investigations on CXCL13 in anti-N-methyl-D-aspartate receptor encephalitis: a potential biomarker of treatment response","volume":"72","author":"Leypoldt","year":"2015","journal-title":"J Neurol"},{"key":"10.1016\/j.ejpn.2017.11.010_bib14","doi-asserted-by":"crossref","first-page":"e0161656","DOI":"10.1371\/journal.pone.0161656","article-title":"Utility of CSF cytokine\/chemokines as markers of active intrathecal inflammation: comparison of demyelinating, anti-NMDAR and enteroviral encephalitis","volume":"11","author":"Kothur","year":"2016","journal-title":"PLos One"},{"key":"10.1016\/j.ejpn.2017.11.010_bib15","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1474-4422(15)00401-9","article-title":"A clinical approach to diagnosis of autoimmune encephalitis","volume":"15","author":"Graus","year":"2016","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.ejpn.2017.11.010_bib16","doi-asserted-by":"crossref","DOI":"10.1111\/dmcn.13579","article-title":"High sensitivity and specificity in proposed clinical diagnostic criteria for anti-N-methyl-D-aspartate receptor encephalitis","author":"Ho","year":"2017","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.ejpn.2017.11.010_bib17","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1093\/brain\/aws256","article-title":"Antibodies to surface dopamine-2 receptor in autoimmune movement and psychiatric disorders","volume":"135","author":"Dale","year":"2012","journal-title":"Brain"},{"key":"10.1016\/j.ejpn.2017.11.010_bib18","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1097\/WCO.0000000000000351","article-title":"Stiff person syndrome and other immune-mediated movement disorders \u2013 new insights","volume":"29","author":"Balint","year":"2016","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.ejpn.2017.11.010_bib19","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1093\/brain\/awu142","article-title":"Glycine receptor antibodies in PERM and related syndromes: characteristics, clinical features and outcomes","volume":"137","author":"Carvajal-Gonzalez","year":"2014","journal-title":"Brain"},{"key":"10.1016\/j.ejpn.2017.11.010_bib20","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1212\/WNL.0000000000000991","article-title":"DPPX potassium channel antibody: frequency, clinical accompaniments, and outcomes in 20 patients","volume":"83","author":"Tobin","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.ejpn.2017.11.010_bib21","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.parkreldis.2013.10.029","article-title":"Psychiatric disorders in persistent and remitted Sydenham's chorea","volume":"20","author":"Moreira","year":"2014","journal-title":"Park Relat Disord"},{"key":"10.1016\/j.ejpn.2017.11.010_bib22","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1002\/mpo.1139","article-title":"Opsoclonus-myoclonus-ataxia syndrome in neuroblastoma: histopathologic features-a report from the Children's Cancer Group","volume":"36","author":"Cooper","year":"2001","journal-title":"Med Pediatr Oncol"},{"key":"10.1016\/j.ejpn.2017.11.010_bib23","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1136\/jnnp-2011-300411","article-title":"Cognitive deficits following anti-NMDA receptor encephalitis","volume":"83","author":"Finke","year":"2012","journal-title":"J Neurol Neurosurg Psychiatr"},{"key":"10.1016\/j.ejpn.2017.11.010_bib24","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1080\/13854046.2016.1191676","article-title":"Neuropsychological characterization of three adolescent females with anti-NMDA receptor encephalitis in the acute, post-acute, and chronic phases: an inter-institutional case series","volume":"31","author":"Hinkle","year":"2017","journal-title":"Clin Neuropsychol"},{"key":"10.1016\/j.ejpn.2017.11.010_bib25","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1007\/s00415-016-8056-9","article-title":"Cognitive and neuropsychological evolution in children with anti-NMDAR encephalitis","volume":"263","author":"Matricardi","year":"2016","journal-title":"J Neurol"},{"key":"10.1016\/j.ejpn.2017.11.010_bib26","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.neuroscience.2015.05.037","article-title":"Imaging of autoimmune encephalitis\u2013relevance for clinical practice and hippocampal function","volume":"309","author":"Heine","year":"2015","journal-title":"Neuroscience"},{"key":"10.1016\/j.ejpn.2017.11.010_bib27","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1002\/1531-8257(199909)14:5<805::AID-MDS1013>3.0.CO;2-P","article-title":"Persistent Sydenham's chorea","volume":"14","author":"Cardoso","year":"1999","journal-title":"Mov Disord"},{"key":"10.1016\/j.ejpn.2017.11.010_bib28","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.parkreldis.2011.12.013","article-title":"Pregnancy in patients with Sydenham's chorea","volume":"18","author":"Maia","year":"2012","journal-title":"Park Relat Disord"},{"key":"10.1016\/j.ejpn.2017.11.010_bib29","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1111\/dmcn.12594","article-title":"Cerebellar and cortical abnormalities in paediatric opsoclonus-myoclonus syndrome","volume":"57","author":"Anand","year":"2015","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.ejpn.2017.11.010_bib30","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1111\/j.1528-1157.1995.tb01615.x","article-title":"Neuropharmacology of progressive myoclonus epilepsy: response to 5-hydroxy-L-tryptophan","volume":"36","author":"Pranzatelli","year":"1995","journal-title":"Epilepsia"},{"key":"10.1016\/j.ejpn.2017.11.010_bib31","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.braindev.2015.11.007","article-title":"Trends and tenets in relapsing and progressive opsoclonus-myoclonus syndrome","volume":"38","author":"Pranzatelli","year":"2016","journal-title":"Brain Dev"},{"key":"10.1016\/j.ejpn.2017.11.010_bib32","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1176\/appi.ajp.157.2.281","article-title":"MRI assessment of children with obsessive-compulsive disorder or tics associated with streptococcal infection","volume":"157","author":"Giedd","year":"2000","journal-title":"Am J Psychiatr"},{"key":"10.1016\/j.ejpn.2017.11.010_bib33","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00228-011-1161-x","article-title":"Macrolides: from in\u00a0vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases","volume":"68","author":"Zarogoulidis","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.ejpn.2017.11.010_bib34","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1128\/CMR.00078-09","article-title":"Mechanisms of action and clinical application of macrolides as immunomodulatory medications","volume":"23","author":"Kanoh","year":"2010","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ejpn.2017.11.010_bib35","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1159\/000320320","article-title":"Immunomodulatory effects of macrolide antibiotics \u2013 part 2: advantages and disadvantages of long-term, low-dose macrolide therapy","volume":"81","author":"Altenburg","year":"2011","journal-title":"Respiration"},{"key":"10.1016\/j.ejpn.2017.11.010_bib36","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1159\/000320319","article-title":"Immunomodulatory effects of macrolide antibiotics \u2013 part 1: biological mechanisms","volume":"81","author":"Altenburg","year":"2011","journal-title":"Respiration"},{"key":"10.1016\/j.ejpn.2017.11.010_bib37","first-page":"6","article-title":"The anti-inflammatory effects of tetracyclines","volume":"75","author":"Weinberg","year":"2005","journal-title":"Cutis"},{"key":"10.1016\/j.ejpn.2017.11.010_bib38","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1056\/NEJMoa1608889","article-title":"Trial of minocycline in a clinically isolated syndrome of multiple sclerosis","volume":"376","author":"Metz","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejpn.2017.11.010_bib39","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1055\/s-0029-1237723","article-title":"Long-term follow-up of neuroblastoma-associated opsoclonus-myoclonus-ataxia syndrome","volume":"40","author":"De Grandis","year":"2009","journal-title":"Neuropediatrics"},{"key":"10.1016\/j.ejpn.2017.11.010_bib40","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1212\/WNL.0000000000000570","article-title":"Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease","volume":"83","author":"Dale","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.ejpn.2017.11.010_bib41","doi-asserted-by":"crossref","first-page":"580","DOI":"10.4049\/jimmunol.1400118","article-title":"Rituximab efficiently depletes increased CD20-expressing T cells in multiple sclerosis patients","volume":"193","author":"Palanichamy","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.ejpn.2017.11.010_bib42","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1186\/s13075-016-1101-3","article-title":"Rituximab induces phenotypical and functional changes of NK cells in a non-malignant experimental setting","volume":"18","author":"Merkt","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.ejpn.2017.11.010_bib43","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/nri.2017.1","article-title":"Immune regulation by glucocorticoids","volume":"17","author":"Cain","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.ejpn.2017.11.010_bib44","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1002\/acr.21641","article-title":"2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis","volume":"64","author":"Singh","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"10.1016\/j.ejpn.2017.11.010_bib45","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1586\/14737175.2015.1115720","article-title":"Immune therapy in autoimmune encephalitis: a systematic review","volume":"15","author":"Nosadini","year":"2015","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.ejpn.2017.11.010_bib46","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1177\/0883073811414058","article-title":"Treatment of sydenham chorea with intravenous immunoglobulin","volume":"27","author":"Walker","year":"2012","journal-title":"J Child Neurol"},{"key":"10.1016\/j.ejpn.2017.11.010_bib47","doi-asserted-by":"crossref","first-page":"456","DOI":"10.5334\/tohm.376","article-title":"Treatment of Sydenham's chorea: a review of the current evidence","volume":"7","author":"Dean","year":"2017","journal-title":"Tremor Other Hyperkinet Mov (N Y)"},{"key":"10.1016\/j.ejpn.2017.11.010_bib48","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40734-014-0012-1","article-title":"Severe Sydenham's chorea (chorea paralytica) successfully treated with plasmapheresis","volume":"2","author":"Miranda","year":"2015","journal-title":"J Clin Mov Disord"},{"key":"10.1016\/j.ejpn.2017.11.010_bib49","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1177\/08830738050200050601","article-title":"Treatment of Sydenham's chorea with intravenous immunoglobulin, plasma exchange, or prednisone","volume":"20","author":"Garvey","year":"2005","journal-title":"J Child Neurol"},{"key":"10.1016\/j.ejpn.2017.11.010_bib50","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1177\/0883073814549581","article-title":"Effect of increased immunosuppression on developmental outcome of opsoclonus myoclonus syndrome (OMS)","volume":"30","author":"Mitchell","year":"2015","journal-title":"J Child Neurol"},{"key":"10.1016\/j.ejpn.2017.11.010_bib51","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1177\/0883073811428816","article-title":"Active comparator-controlled, rater-blinded study of corticotropin-based immunotherapies for opsoclonus-myoclonus syndrome","volume":"27","author":"Tate","year":"2012","journal-title":"J Child Neurol"},{"key":"10.1016\/j.ejpn.2017.11.010_bib52","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1097\/01.mph.0000212991.64435.f0","article-title":"Rituximab (anti-CD20) adjunctive therapy for opsoclonus-myoclonus syndrome","volume":"28","author":"Pranzatelli","year":"2006","journal-title":"J Pediatr Hematol Oncol"},{"key":"10.1016\/j.ejpn.2017.11.010_bib53","doi-asserted-by":"crossref","DOI":"10.1089\/cap.2016.0190","article-title":"A double-blind randomized placebo-controlled pilot study of azithromycin in youth with acute-onset obsessive-compulsive disorder","author":"Murphy","year":"2017","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.ejpn.2017.11.010_bib54","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/S0140-6736(98)12297-3","article-title":"Therapeutic plasma exchange and intravenous immunoglobulin for obsessive-compulsive disorder and tic disorders in childhood","volume":"354","author":"Perlmutter","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.ejpn.2017.11.010_bib55","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.jaac.2016.06.017","article-title":"Randomized, controlled trial of intravenous immunoglobulin for pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections","volume":"55","author":"Williams","year":"2016","journal-title":"J Am Acad Child Adolesc Psychiatr"},{"key":"10.1016\/j.ejpn.2017.11.010_bib56","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.braindev.2016.01.009","article-title":"Plasma exchange in pediatric anti-NMDAR encephalitis: a systematic review","volume":"38","author":"Suppiej","year":"2016","journal-title":"Brain Dev"},{"key":"10.1016\/j.ejpn.2017.11.010_bib57","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.pediatrneurol.2005.08.028","article-title":"Randomized double-blind study with prednisone in Sydenham's chorea","volume":"34","author":"Paz","year":"2006","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.ejpn.2017.11.010_bib58","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1177\/1756285610382063","article-title":"An update on the treatment of Sydenham's chorea: the evidence for established and evolving interventions","volume":"3","author":"Walker","year":"2010","journal-title":"Therapeut Adv Neurol Disord"},{"key":"10.1016\/j.ejpn.2017.11.010_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.pediatrneurol.2017.04.027","article-title":"Dexamethasone, IVIg, and rituximab combination immunotherapy for pediatric opsoclonus-myoclonus syndrome","author":"Pranzatelli","year":"2017","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.ejpn.2017.11.010_bib60","doi-asserted-by":"crossref","first-page":"e130","DOI":"10.1212\/NXI.0000000000000130","article-title":"Earlier treatment of NMDAR antibody encephalitis in children results in a better outcome","volume":"2","author":"Byrne","year":"2015","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"10.1016\/j.ejpn.2017.11.010_bib61","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/S1474-4422(08)70224-2","article-title":"Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies","volume":"7","author":"Dalmau","year":"2008","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.ejpn.2017.11.010_bib62","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ejpn.2007.05.005","article-title":"Chronic relapsing opsoclonus-myoclonus syndrome: combination of cyclophosphamide and dexamethasone pulses","volume":"12","author":"Wilken","year":"2008","journal-title":"Eur J Paediatr Neurol"},{"key":"10.1016\/j.ejpn.2017.11.010_bib63","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1177\/0883073808324217","article-title":"Insights on chronic-relapsing opsoclonus-myoclonus from a pilot study of mycophenolate mofetil","volume":"24","author":"Pranzatelli","year":"2009","journal-title":"J Child Neurol"},{"key":"10.1016\/j.ejpn.2017.11.010_bib64","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/dmcn.12882","article-title":"Symptomatic treatment of children with anti-NMDAR encephalitis","volume":"58","author":"Mohammad","year":"2016","journal-title":"Dev Med Child Neurol"},{"key":"10.1016\/j.ejpn.2017.11.010_bib65","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S1474-4422(16)00132-0","article-title":"Advances in management of movement disorders in children","volume":"15","author":"Koy","year":"2016","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.ejpn.2017.11.010_bib66","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1136\/jnnp.74.9.1350-a","article-title":"Sydenham's chorea may be a risk factor for drug induced parkinsonism","volume":"74","author":"Teixeira","year":"2003","journal-title":"J Neurol Neurosurg Psychiatr"},{"key":"10.1016\/j.ejpn.2017.11.010_bib67","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1177\/0883073807302614","article-title":"Sydenham's chorea: a clinical follow-up of 65 patients","volume":"22","author":"Demiroren","year":"2007","journal-title":"J Child Neurol"},{"key":"10.1016\/j.ejpn.2017.11.010_bib68","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1002\/mds.20377","article-title":"UFMG Sydenham's chorea rating scale (USCRS): reliability and consistency","volume":"20","author":"Teixeira","year":"2005","journal-title":"Mov Disord"},{"key":"10.1016\/j.ejpn.2017.11.010_bib69","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1097\/00002826-200111000-00007","article-title":"Controlled pilot study of piracetam for pediatric opsoclonus-myoclonus","volume":"24","author":"Pranzatelli","year":"2001","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.ejpn.2017.11.010_bib70","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/WCO.0000000000000443","article-title":"Autoimmune encephalitis in children: clinical phenomenology, therapeutics, and emerging challenges","volume":"30","author":"Dale","year":"2017","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.ejpn.2017.11.010_bib71","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/nyas.12553","article-title":"Autoimmune encephalopathies","volume":"1338","author":"Leypoldt","year":"2015","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.ejpn.2017.11.010_bib72","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1586\/14737175.2015.1115720","article-title":"Immune therapy in autoimmune encephalitis: a systematic review","volume":"15","author":"Nosadini","year":"2015","journal-title":"Expert Rev Neurother"}],"container-title":["European Journal of Paediatric Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1090379817317348?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1090379817317348?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,24]],"date-time":"2020-10-24T14:34:59Z","timestamp":1603550099000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1090379817317348"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":72,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,3]]}},"alternative-id":["S1090379817317348"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpn.2017.11.010","relation":{},"ISSN":["1090-3798"],"issn-type":[{"value":"1090-3798","type":"print"}],"subject":[],"published":{"date-parts":[[2018,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Principles and approaches to the treatment of immune-mediated movement disorders","name":"articletitle","label":"Article Title"},{"value":"European Journal of Paediatric Neurology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpn.2017.11.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier Ltd on behalf of European Paediatric Neurology Society.","name":"copyright","label":"Copyright"}]}}